Shots:

• The P-I/IIa (CANFOUR) trial evaluates nadunolimab + CT (gemcitabine & nab-paclitaxel) in patients with PDAC. The results are expected in H1’22
• In interim results, the therapy showed median survival (12.7mos. vs 8.5mos.) over historical data in patients with gemcitabine & nab-paclitaxel, 1yr. survival rate (55% vs 35%), m-iPFS (7.2mos.) & 6mos. iPFS (56%), 2 patients continued on treatment & 12 patients were still alive, safety & response rates are similar to previous results
• The results showed m-PFS (5.5mos.) with a 6mos. PFS of 44% in patients with CT. The therapy is being evaluated in multiple trials while the company is planning for a randomized & pivotal trial for pancreatic cancer

Ref: Cision | Image: LinkedIn